A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma

Trial Profile

A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Bendamustine; Rituximab
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Therapeutic Use
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 30 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 30 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 19 May 2017 This trial has been completed in Spain as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top